Significant Progress with OncoMimics™ and EndoMimics™ pipelines of transformational medicines for cancer and immune diseases

On November 4, 2021 Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its unique ability to decode the gut microbiome’s interaction with the immune system, reported the launch of its new corporate brand and visual identity supported by a new website (Press release, Enterome, NOV 4, 2021, View Source [SID1234594562]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These changes reflect the significant progress that Enterome has made with its two advanced, fully owned, OncoMimics and EndoMimics pipelines of transformational medicines for cancer and immune diseases, respectively.

Enterome’s most advanced OncoMimics drug candidates are:

EO2401, a therapeutic cancer vaccine candidate currently in clinical development for recurrent glioblastoma and adrenal tumors. EO2401 has already shown strong immunogenicity data in brain and adrenal cancer patients with clinical proof of concept data expected in H1 2022, and
EO2463, a second OncoMimic cancer vaccine, in clinical development for the treatment of indolent non-Hodgkin lymphoma with clinical proof of concept data planned for H1 2023
In addition, the Company’s most advanced EndoMimics candidate is:

EB1010, a new orally delivered bioactive and a potent local inducer of IL-10, which has been selected to provide improved therapeutic outcomes for patients with inflammatory bowel disease (IBD). EB1010 is expected to enter clinical trial in 2023
The Enterome name was created using a combination of the Greek prefix "ENTER", which means ’from the gut’ and the suffix of gen’OME’. This name highlights Enterome’s world-leading ability to interrogate the collective gut microbiome genome to identify and characterize bioactive proteins and peptides as a foundation to generate novel therapeutic vaccines and biological drugs.

Enterome’s drug discovery platform leverages a unique combination of biocomputational tools and bioassays, to explore new therapeutic solutions from the world’s largest database of 20 million functionally annotated full-length gut microbiome proteins. This use of cutting-edge tools means that Enterome’s platform is more efficient than well established, labor-intensive drug discovery approaches. Enterome’s platform has already demonstrated it is highly productive and has generated multiple pipelines of transformative drug candidates, targeting a broad range of therapeutic areas.

Morphic Announces Corporate Highlights and Third Quarter 2021 Financial Results

On November 4, 2021 Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, reported corporate highlights and financial results for the third quarter of 2021 (Press release, Morphic Therapeutic, NOV 4, 2021, View Source [SID1234594561]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Recent Highlights and Outlook

Presented positive phase 1 data at the European Crohn’s and Colitis Organisation (ECCO) Virtual Congress 2021, fully supporting MORF-057’s target product profile as an oral inhibitor of the α4β7 integrin
MORF-057 was well tolerated in all dose cohorts with no safety signals identified
Pharmacodynamic data, including α4β7 receptor saturation at 100 mg BID administered orally, strongly supported MORF-057’s ability to replicate the mechanism of approved therapeutic vedolizumab, administered via IV infusion
MORF-057’s dose-dependent and consistent pharmacokinetic data support twice daily dosing profile and enable plans to evaluate once-daily dosing in phase 2b
Lymphocyte subset changes strongly demonstrate early in-human evidence for MORF-057’s small molecule α4β7 inhibition to replicate the published data on mechanism of action from approved biologic therapeutics in inflammatory bowel disease (IBD)
Planned initiation of MORF-057 phase 2a remains on track for first quarter 2022
All phase 2 readiness work, including chronic toxicology studies, on track and scheduled for completion in fourth quarter 2021
Study to include 30-35 patients with moderate to severe ulcerative colitis treated with 100 mg BID (twice daily) with 12-week induction phase and rollover to 40 additional weeks maintenance phase in patients
The primary endpoint is change in Robarts Histopathologic Index (RHI) at 12 weeks
Global phase 2b randomized controlled trial of MORF-057 to commence after phase 2a initiation and then run in parallel
Welcomed Nisha Nanda, Ph.D., to the Morphic Board of Directors, an experienced leader in preclinical and clinical-stage development strategy across multiple therapeutic areas
Received acceptance to present preclinical data from our αvβ8 inhibitor program at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Annual Meeting
Announced the planned resignation of Peter G. Linde, M.D., Chief Medical Officer, effective December 31, 2021. Dr. Linde has notified the Company that he is departing for personal reasons but will remain with the Company through year end to assist with an orderly transition of responsibilities
"MORF-057’s performance in phase 1 studies exceeded our internal modelling across all key criteria and we are now finalizing preparations for the initiation of the MORF-057 phase 2 program in patients with moderate-to-severe ulcerative colitis," said Praveen Tipirneni, M.D., President and Chief Executive Officer of Morphic Therapeutic. "Developing MORF-057 with our MInT platform has generated an array of learnings that feed into our earlier proprietary pipeline, driving advances in Morphic’s programs in immuno-oncology and other indications. In particular, we are looking forward to the presentation of new preclinical data from our αvβ8 program demonstrating the strong anti-tumor activity of a Morphic αvβ8 small molecule inhibitor dosed in combination with a checkpoint inhibitor and radioimmunotherapy in a tumor that is unresponsive to respective monotherapies or conventional radioimmunotherapy."

Financial Results for the Third Quarter 2021

Net loss for the quarter ended September 30, 2021 was $25.0 million or $0.69 per share, basic and diluted compared to net income of $5.4 million or $0.17 per share, diluted for the same quarter last year
Revenue was $3.1 million for the quarter ended September 30, 2021, compared to $25.8 million for the same quarter last year. The decrease was primarily due to the receipt of a $20 million payment triggered by AbbVie exercising their option to Morphic’s αvβ6 program during the quarter ended September 30, 2020
Research and development expenses were $21.0 million for the quarter ended September 30, 2021 as compared to $16.0 million for the same quarter last year. The increase was primarily due to clinical trial costs associated with MORF-057, along with manufacturing costs associated with the upcoming phase 2 clinical trial
General and administrative expenses were $7.3 million for the quarter ended September 30, 2021, compared to $4.8 million for the same quarter last year. The increase was due to an increase in headcount and higher professional and consulting costs associated with Morphic operating as a public company
As of September 30, 2021, Morphic had cash, cash equivalents and marketable securities of $427.6 million, compared to $228.3 million as of December 31, 2020. Morphic believes its cash, cash equivalents and marketable securities as of September 30, 2021, will be sufficient to fund operating expenses and capital expenditure requirements until the end of 2024.

Vaxart Provides Business Update and Reports Third Quarter 2021 Financial Results

On November 4, 2021 Vaxart, Inc. (NASDAQ: VXRT) reported its business update today for the third quarter of 2021, reporting strong forward momentum in developing its oral vaccine platform consisting of tablet vaccines that it believes may revolutionize public health (Press release, Vaxart, NOV 4, 2021, View Source [SID1234594560]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the third quarter, Vaxart started the first Phase II trial of its investigational COVID-19 oral tablet vaccine and dosed its first subjects. Vaxart expects the full data set from this study to be available in Q1 2022.

Duke University published the results of its study of Vaxart’s COVID-19 vaccine candidate, finding that Vaxart’s oral tablet vaccine reduced the airborne transmission of SARS-CoV-2 virus in a hamster preclinical model.

The Company also expanded its research and manufacturing capabilities, enhancing its ability to advance its pipeline of vaccine candidates.

"Vaxart made significant progress this quarter toward its goal of developing a next-generation oral tablet COVID-19 vaccine," said Andrei Floroiu, Vaxart’s Chief Executive Officer. "We have started our United States Phase II trial and anticipate beginning international trials in the near future. This is an important milestone, as our candidate is the only oral COVID-19 vaccine to progress to Phase II trials in the U.S."

"Our view has been that an oral tablet vaccine could transform how the world is protected from COVID-19 and other infections because they are easy to distribute and administer. Now we added evidence suggesting the differentiated mucosal mechanism of action could be yet another improvement over injectable alternatives," added Mr. Floroiu.

"The progress we made in our vaccine research this quarter was significant," said Dr. Sean Tucker, Vaxart’s founder and Chief Scientific Officer. "We already learned from an earlier human influenza challenge study that our oral flu vaccine candidate inhibited the shedding of viral RNA better than injectable vaccines. Our published hamster study showed that our vaccine candidate can reduce transmission of SARS-CoV-2, even when there is infection breakthrough in a vaccinated subject."

"The implications are significant because existing injected vaccines do not always protect against viral shedding and transmission to other people. A vaccine that reduces shedding and reduces the probability of infection could make a big difference in protecting lives and public health."

Recent Business Highlights

Corporate Developments

Vaxart recently brought online its own GMP manufacturing facility and is now producing vaccines at two GMP plants. This has allowed the Company to manufacture all of the COVID-19 vaccine oral tablets for the clinical trials started and planned to start this year, and to begin manufacturing vaccines for its upcoming norovirus Phase II trials.
Vaxart scaled up its research, quality and manufacturing capabilities, increasing its R&D employee headcount by more than 35% during the quarter.
The Company created two advisory boards, the Scientific and Clinical Advisory Board and the Manufacturing and Quality Advisory Board, to provide expertise as the Company grows its scientific and manufacturing capabilities.
Vaxart named Dr. James F. Cummings as its Chief Medical Officer. Dr. Cummings is a board-certified infectious disease physician with extensive experience in vaccine, drug and diagnostics development, and will help guide the Company’s development of its vaccines.
Widely respected biotech executive Dr. Julie Cherrington joined Vaxart’s Board of Directors, deepening the pool of expertise on its board.
Preclinical and Clinical

Clinical COVID-19 Vaccine Developments

Vaxart made significant progress in Q3 2021 to advance its transformative approach to vaccines.

Vaxart began dosing subjects in October for its Phase II clinical trial in the United States, which is expected to enroll 96 subjects.
The Company expects data from this study to be available during Q1 2022.
The study will be conducted with subjects split evenly between COVID-19 naïve and mRNA vaccinated subjects.
During Q4 2021, Vaxart expects to start Phase Ib clinical testing in India.
The Company expects to launch additional international clinical trials in 1H 2022.
Preclinical COVID-19 Vaccine Developments

A Duke University-led study published in bioRxiv in October showed that Vaxart’s investigational oral tablet vaccine candidate reduced the airborne transmission of SARS-CoV-2 virus in a hamster model.
These results are consistent with those from Vaxart’s Phase II human flu challenge study, which showed that Vaxart’s oral tablet flu vaccine was better at reducing shedding than the injectable flu vaccine comparator.
Vaxart’s preclinical study also demonstrated that the Company’s oral vaccine platform induces robust systemic and mucosal responses.
The study suggested that mucosal vaccines may protect not only vaccinated, but also unvaccinated animals.
Vaxart will submit the results of its nonhuman primate study for publication in Q4 2021. Results from that study prompted Vaxart to move forward with its S-only vaccine candidate in Phase II clinical trials. This S-only vaccine candidate produced better antibody responses and cross-reactivity against all variants tested than Vaxart’s S+N vaccine candidate.
Norovirus Vaccine Developments

Norovirus is a highly infectious illness that affects around 20 million Americans annually, with an annual economic impact of approximately $10.5 billion in the United States.

Vaxart has almost completed enrollment in its Phase Ib placebo-controlled, dose-ranging, repeat dose trial investigating its oral norovirus vaccine candidate in elderly subjects aged 55 to 80 years. This study is designed to evaluate the safety and immunogenicity of Vaxart’s vaccine candidate.
The Company anticipates completing enrollment in its norovirus VXA-G1.1-104 study in Q4 2021.
Vaxart is also conducting an additional norovirus vaccine study to evaluate the optimal timing for boost administration under VXA-NVV-105. This study has completed enrollment.
The Company expects initial data to be available from these studies in Q1 2022 and more complete data by Q2 2022.
Vaxart is preparing to launch its norovirus challenge study in Q1 2022 to evaluate the safety and clinical efficacy of its oral vaccine candidate.
Manufacturing Updates

As noted above, Vaxart is now producing vaccines at two GMP manufacturing plants in California, including its own GMP manufacturing facility.
As a result, Vaxart has produced the tablets for its Phase II and Phase Ib COVID-19 studies and is starting to produce norovirus vaccine for additional clinical studies.
Financial Results for the Three Months Ended September 30, 2021

Vaxart ended the quarter with cash, cash equivalents and available-for-sale debt securities of $204.0 million, compared to $198.9 million as of June 30, 2021. The increase was primarily due to net receipts of $20.3 million from the Company’s $250 million at-the-market facility entered into in October 2020 and $0.3 million from the exercise of warrants and options, partially offset by $14.2 million of cash used in operations and $1.3 million spent on property and equipment.
The Company reported a net loss of $17.6 million for the third quarter of 2021, compared to $8.1 million for the third quarter of 2020. Net loss per share for the third quarter of 2021 was $0.14, compared to a net loss of $0.08 per share in the third quarter of 2020. The increase in net loss per share was primarily due to the increase in net loss, resulting from a significant increase in research and development expenses.
Revenue for the third quarter of 2021 was $200,000, compared to $265,000 in the third quarter of 2020. The decrease was due to lower royalty revenue from sales of Inavir in Japan.
Research and development expenses were $12.4 million for the third quarter of 2021, compared to $4.6 million for the third quarter of 2020. The increase was mainly due to increases in headcount and related costs and in manufacturing and clinical trial expenses related to our COVID-19 and norovirus vaccine candidates.
General and administrative expenses were $5.0 million for the third quarter of 2021, compared to $4.2 million for the third quarter of 2020. The increase was mainly due to an increase in headcount and related costs.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

EpiVax licenses Tregitope Technology to Maruho Co., Ltd. for development of Tregitope-based Therapies to Treat Autoimmune Condition

On November 4, 2021 EpiVax, Inc. ("EpiVax") reported an important commercial licensing agreement with Maruho Co., Ltd. ("Maruho") for EpiVax’s patented Tregitope technology (Press release, EpiVax, NOV 4, 2021, View Source [SID1234594558]). This marks an exciting step for Maruho and EpiVax towards continued expansion of the Tregitope program and translation to the clinic.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Tregitopes are immune-modulating peptides derived from human immunoglobulin. Tregitopes were first discovered in 2008 by EpiVax co-founders Dr. Anne De Groot and William Martin. EpiVax has since validated many more Tregitopes and has developed a strong Tregitope patent estate. With a wide range of therapeutic applications, Tregitopes can be co-formulated or fused to proteins to induce antigen-specific tolerance. EpiVax is currently licensing Tregitope for additional indications with commercial and academic partners. More information on the EpiVax Tregitope Platform is available here.

Similar to intravenous immunoglobulin G (IVIG) therapy, Tregitopes engage regulatory T cells and downregulate inflammation in a wide range of disease models. This mechanism of action has been studied in academic collaborations at McGill University, Harvard Medical School, and undisclosed commercial partners. There have been many peer-reviewed publications on the Tregitope platform in recent years. A full list can be found here.

Maruho will be able to leverage their Tregitope license to enhance their in-house therapeutic development strategies for autoimmune conditions. Annie De Groot MD, CEO/CSO of EpiVax, said "This agreement reflects the potential for Tregitopes, natural Treg epitopes that help regulate immune responses, to be used for the treatment of conditions that afflict patients around the world".

Castle Biosciences’ Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA® Electronic Health Records System

On November 4, 2021 Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative diagnostics to inform disease management decisions and improve patient outcomes, reported its agreement with ModMed to establish an interface with ModMed’s electronic health records system, EMA (Press release, Castle Biosciences, NOV 4, 2021, View Source [SID1234594543]). The interface is designed to enable dermatologic clinicians to order Castle’s DecisionDx skin cancer tests from directly within a patient’s medical record in EMA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At Castle, we are excited to facilitate the ordering of our skin cancer portfolio from directly within one of the most widely utilized dermatologic electronic health records systems, EMA," said Toby Juvenal, chief commercial officer of Castle Biosciences. "We are committed to impacting patient care, and our diagnostic tests are designed to provide clinically-actionable information to clinicians and patients to inform disease management decisions. The EMA platform has been ranked #1 by dermatologists for the past eight years by Black Book. Our interface with this system is expected to streamline the ordering process and allow for delivery of Castle’s test results within the system."

Castle’s full suite of skin cancer tests will be available to order within EMA: DecisionDx-Melanoma for cutaneous melanoma, DecisionDx-SCC for cutaneous squamous cell carcinoma and the Company’s Comprehensive Diagnostic Offering for difficult-to-diagnose melanocytic lesions (comprised of myPath Melanoma and DecisionDx DiffDx-Melanoma). Castle’s interface with EMA is expected to be complete by year-end 2021.